Abstract Coronavirus disease 2019 (COVID-19) predisposes patients to thrombotic and
thromboembolic events, owing to excessive inflammation, endothelial cell activation and …

Hyperactivation of the complement and coagulation systems is recognized as part of the
clinical syndrome of COVID-19. Here we review systemic complement activation and local …

Abstract Coronavirus disease 2019 (COVID-19) is a clinical syndrome caused by infection
with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients with severe …

Strong evidence has been accumulated since the beginning of the COVID-19 pandemic that
neutrophils play an important role in the pathophysiology, particularly in those with severe …

Background Frequent use of antibiotics in patients with COVID-19 threatens to exacerbate
antimicrobial resistance. We aimed to establish the prevalence and predictors of bacterial …

During severe inflammatory and infectious diseases, various mediators modulate the
equilibrium of vascular tone, inflammation, coagulation and thrombosis. This Review …

Background Vilobelimab, an anti-C5a monoclonal antibody, was shown to be safe in a
phase 2 trial of invasively mechanically ventilated patients with COVID-19. Here, we aimed …

COVID-19 is a primary respiratory illness that is frequently complicated by systemic
involvement of the vasculature. Vascular involvement leads to an array of complications …

Objective: Coronavirus disease 2019 is a heterogeneous disease most frequently causing
respiratory tract infection, which can induce respiratory failure and multiple organ …

Microvascular thrombosis is associated with multiorgan failure and mortality in coronavirus
disease 2019 (COVID-19). Although thrombotic complications may be ascribed to the ability …